Overview
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
Status:
Recruiting
Recruiting
Trial end date:
2023-09-10
2023-09-10
Target enrollment:
0
0
Participant gender:
All
All
Summary
The goal of this study is to investigate that a common cholesterol lowering agent (atorvastatin) alone or combining with a nonsteroidal anti-inflammatory drug (aspirin) would reduce the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.Phase:
Early Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Fox Chase Cancer CenterTreatments:
Aspirin
Atorvastatin
Criteria
Inclusion Criteria:- Subjects who are 18 years of age or older
- Able to read and sign an informed consent document in English
- Eligible subjects will have molecular evidence of Lynch Syndrome (mutation in MLH1,
MSH2, MSH6, EPCAM or PMS2)
- History of colorectal cancer if surgically cured and > 1 year from completion of
adjuvant chemotherapy
Exclusion Criteria:
- Are <18 years of age
- Unable to read and sign an informed consent document in English
- Have active cancer or are less than 3 years post hormonal maintenance therapy for
cancer
- Have statin intolerance or contraindication for aspirin or atorvastatin use
- Are pregnant or are actively breast feeding